IgLON5 autoimmune antibodies activate Tau via neuronal hyperactivity

Read full text
Authors: Bilge Askin, Cagla Kilic, César Cordero Gómez, Sophie Lan-Linh Duong, Alvaro Domingues-Baquero, Alexander Goihl, Karsten Nalbach, Joana Petushi, Pia Grundschöttel, Jessica Wagner, Valentine Thomas, Janne Lamberty
+19 more Emily Withers, Hanna Huber, Sabrina Huebschmann, Ekaterina Semenova, Paul Turko, Andrew G. Newman, Lisa Diez, Marc Beyer, Elena De Domenico, Péter Körtvelyessy, Dirk Reinhold, Anja Schneider, Jonas J. Neher, T Ulas, Stefan F. Lichtenthaler, Benjamin R. Rost, Dietmar Schmitz, Harald Prüss, Susanne Wegmann
Cited by: 1
References: 113

Abstract

Anti-IgLON5 disease is an autoimmune disease, in which autoantibodies (AABs) against the neuronal cell surface protein IgLON5 lead to profound brain dysfunction and Tau pathology. How α-IgLON5 AABs cause neuronal Tau protein pathology and neurodegeneration remains unclear. We find that patient-derived α-IgLON5 AABs cluster IgLON5 proteins with other cell surface proteins, leading to neuronal hyperactivity that triggers pathological Tau missorting and phosphorylation, typically observed early in Tau-related neurodegenerative diseases. In wild-type mice, α-IgLON5 AABs induce hippocampal Tau phosphorylation and neuroinflammatory responses. Our findings establish a causal link between the α-IgLON5 AABs and Tau pathology in anti-IgLON5 disease patients and highlight the role of neuronal hyperactivity as a disease-overarching driver of Tau pathology and provide a potential target for therapeutic intervention.

Fields of Study & Subjects

Autoimmune Neurological Disorders and Treatments Neuroinflammation and Neurodegeneration Mechanisms Peripheral Neuropathies and Disorders

Publication details

Journal / source
Science Advances
Publisher
American Association for the Advancement of Science (AAAS)
Volume
12
Issue
20
Pages
eaec2042–eaec2042
Publication date
13 May 2026
Language
EN